XTRP2 Activators
XTRP2 activators operate through a variety of biochemical mechanisms, mainly involving the modulation of cyclic nucleotide levels within cells. The activation of adenylate cyclase by certain compounds leads to increased concentrations of cAMP, which engages specific signaling pathways that XTRP2 is a part of, thus enhancing the function of this solute carrier protein. These pathways include those mediated by G-protein-coupled receptor signaling, where increased cAMP acts as a second messenger to relay intracellular signals. Similarly, the inhibition of phosphodiesterase enzymes by different molecules results in elevated cAMP and cGMP levels, which may further stimulate XTRP2 activity through the amplification of cyclic nucleotide-mediated signaling. Some activators specifically target phosphodiesterases associated with the breakdown of cAMP, while others influence the cGMP-specific enzymes, both ultimately leading to the potential activation of XTRP2 by maintaining high levels of these signaling molecules.
Another set of activators work by modulating the cellular response to energy status and the availability of adenosine triphosphate (ATP). For instance, certain molecules activate AMP-activated protein kinase, which is known to respond to changes in cellular energy levels, subsequently influencing the activity of XTRP2. In addition, the blockade of adenosine receptors prevents the natural inhibition of adenylate cyclase, thereby promoting cAMP accumulation and further supporting XTRP2 activation.
| Product Name | CAS # | Catalog # | QUANTITY | Price | Citations | RATING |
|---|---|---|---|---|---|---|
Isoproterenol Hydrochloride | 51-30-9 | sc-202188 sc-202188A | 100 mg 500 mg | $28.00 $38.00 | 5 | |
A synthetic catecholamine that activates beta-adrenergic receptors, increasing cAMP levels in cells, which could lead to the activation of XTRP2 through cAMP-mediated signaling cascades. | ||||||
IBMX | 28822-58-4 | sc-201188 sc-201188B sc-201188A | 200 mg 500 mg 1 g | $260.00 $350.00 $500.00 | 34 | |
A non-selective inhibitor of phosphodiesterases which increases cAMP and cGMP levels in cells, potentially leading to activation of XTRP2 through pathways that are regulated by these cyclic nucleotides. | ||||||
Rolipram | 61413-54-5 | sc-3563 sc-3563A | 5 mg 50 mg | $77.00 $216.00 | 18 | |
Selective inhibitor of phosphodiesterase 4 that increases cAMP levels, which could indirectly lead to the activation of XTRP2 as part of cAMP-mediated signaling processes. | ||||||
PGE2 | 363-24-6 | sc-201225 sc-201225C sc-201225A sc-201225B | 1 mg 5 mg 10 mg 50 mg | $57.00 $159.00 $275.00 $678.00 | 37 | |
Binds to its G-protein-coupled receptors (GPCRs), leading to increased cAMP production, which may result in the activation of XTRP2 through pathways that respond to elevated cAMP. | ||||||
Sodium nitroprusside dihydrate | 13755-38-9 | sc-203395 sc-203395A sc-203395B | 1 g 5 g 100 g | $43.00 $85.00 $158.00 | 7 | |
Releases nitric oxide which activates soluble guanylyl cyclase, increasing cGMP levels and potentially leading to the activation of XTRP2 via cGMP-dependent signaling mechanisms. | ||||||
Dibutyryl-cAMP | 16980-89-5 | sc-201567 sc-201567A sc-201567B sc-201567C | 20 mg 100 mg 500 mg 10 g | $47.00 $136.00 $492.00 $4552.00 | 74 | |
A membrane-permeable analog of cAMP that directly increases intracellular cAMP levels, potentially activating XTRP2 as a result of enhanced cAMP signaling. | ||||||
A-769662 | 844499-71-4 | sc-203790 sc-203790A sc-203790B sc-203790C sc-203790D | 10 mg 50 mg 100 mg 500 mg 1 g | $184.00 $741.00 $1076.00 $3417.00 $5304.00 | 23 | |
Activates AMP-activated protein kinase (AMPK), which could lead to the activation of XTRP2 in response to changes in cellular energy status and AMPK signaling. | ||||||
ZM 241385 | 139180-30-6 | sc-361421 sc-361421A | 5 mg 25 mg | $92.00 $356.00 | 1 | |
An adenosine A2A receptor antagonist that can increase cAMP levels by preventing the inhibitory action of adenosine on adenylate cyclase, which might lead to the activation of XTRP2 via cAMP-dependent pathways. | ||||||
YC-1 | 170632-47-0 | sc-202856 sc-202856A sc-202856B sc-202856C | 1 mg 5 mg 10 mg 50 mg | $33.00 $124.00 $218.00 $947.00 | 9 | |
Increases cGMP levels by sensitizing soluble guanylyl cyclase to endogenous nitric oxide, potentially leading to the activation of XTRP2 through cGMP-dependent signaling. | ||||||